Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism
Key facts
- Where
- Dhaka, BangladeshSee the site
Where in Bangladesh
- Endocrine HTN ClinicDhaka, BangladeshTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bangladesh Medical University
- Trial code
- NCT07688928
- Record updated
- 7 July 2026
- Original description
The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.Read full original descriptionShow less
The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.
It will be a randomized, double-blind, active-controlled, parallel-group clinical trial conducted at the Endocrine Hypertension Clinic, Department of Endocrinology, BSMMU. A total of 104 adult patients with confirmed primary aldosteronism will be enrolled and randomized equally to receive either finerenone (10-40 mg/day) or spironolactone (25-100mg/day) for 48 weeks. Study drugs will be titrated to achieve target blood pressure (<140/90mmHg) and unsuppressed plasma renin concentration (>15 mU/L). The primary efficacy outcome will be the time and daily dose required to attain this composite endpoint. Secondary outcomes include changes in clinic and ambulatory blood pressure, plasma aldosterone and renin levels, renal function (eGFR), urinary albumin excretion, left ventricular mass index, and quality of life. Safety outcomes will include adverse events, particularly hyperkalaemia and deterioration of renal function.
Inclusion: Age >18 years; History of hypertension (blood pressure >140/90 mm Hg), both newly detected and already established patients; Diagnosed case of primary aldosteronism (PA) based on a screening test (increased aldosterone renin ration (ARR) >70pmol/L) and confirmed by saline suppression test (post-saline PAC >170pmol/L, where PAC measured by immunoassay); Serum potassium ≥2.5 mmol/L.
Exclusion: Recent cardiovascular events like acute myocardial ischemia, heart failure with hospitalization, stroke or transient ischemic attack ≤3 months before the screening visit; Uncontrolled hypertension (>180/120 mm Hg); Hepatic insufficiency (Child-Pugh C); Addison's disease; Patient with other form of secondary HTN (e.g. renovascular HTN, Cushing syndrome, pheochromocytoma, coarctation of aorta etc.); Known hypersensitivity to the study drugs; Patients receiving medications confounding PAC or PRC (glucocorticoids, sodium glucose co-transporter 2 inhibitors (SGLT-2i) or systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors (e.g. itraconazole, clarithromycin, rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz) that cannot be discontinued 14 days prior to randomization or for the duration of treatment period; Abnormal renal function test: eGFR <60 ml/min-1.73m2; Serum potassium level >5 mmol/L; Uncontrolled DM (HbA1C >12%); Lateralized PA patients (aldosterone producing adenoma or unilateral hyperplasia) who want to undergo adrenalectomy or having aldosterone producing carcinoma; Participants already with mineralocorticoid receptor antagonist treatment; Pregnant and lactating women. Women with child bearing potential must agree to use adequate contraception during and until 2 month of the end of study period; Patients unwilling to participate in this study.